vs
Side-by-side financial comparison of GAXOS.AI INC. (GXAI) and PLUS THERAPEUTICS, INC. (PSTV). Click either name above to swap in a different company.
PLUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.4M vs $1.2M, roughly 1.1× GAXOS.AI INC.). GAXOS.AI INC. runs the higher net margin — -77.2% vs -417.9%, a 340.7% gap on every dollar of revenue. On growth, GAXOS.AI INC. posted the faster year-over-year revenue change (94996.3% vs -3.2%).
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
GXAI vs PSTV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.4M |
| Net Profit | $-957.9K | $-5.7M |
| Gross Margin | — | — |
| Operating Margin | -99.0% | -420.0% |
| Net Margin | -77.2% | -417.9% |
| Revenue YoY | 94996.3% | -3.2% |
| Net Profit YoY | -15.1% | -46.4% |
| EPS (diluted) | $-0.13 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $1.4M | ||
| Q3 25 | $498.3K | $1.4M | ||
| Q2 25 | $171.0K | $1.4M | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | $0 | $1.3M | ||
| Q1 24 | — | $1.7M |
| Q4 25 | $-957.9K | $-5.7M | ||
| Q3 25 | $-1.0M | $-4.4M | ||
| Q2 25 | $-749.4K | $5.2M | ||
| Q1 25 | — | $-17.4M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | — | $-2.9M | ||
| Q2 24 | $-809.2K | $-2.9M | ||
| Q1 24 | — | $-3.3M |
| Q4 25 | -99.0% | -420.0% | ||
| Q3 25 | -263.9% | -320.8% | ||
| Q2 25 | -574.8% | -110.6% | ||
| Q1 25 | — | -333.9% | ||
| Q4 24 | — | -276.2% | ||
| Q3 24 | — | -260.9% | ||
| Q2 24 | — | -289.1% | ||
| Q1 24 | — | -196.7% |
| Q4 25 | -77.2% | -417.9% | ||
| Q3 25 | -201.0% | -316.6% | ||
| Q2 25 | -438.3% | 370.6% | ||
| Q1 25 | — | -1643.2% | ||
| Q4 24 | — | -276.4% | ||
| Q3 24 | — | -197.4% | ||
| Q2 24 | — | -229.9% | ||
| Q1 24 | — | -194.5% |
| Q4 25 | $-0.13 | $0.95 | ||
| Q3 25 | $-0.14 | $-0.04 | ||
| Q2 25 | $-0.11 | $-0.01 | ||
| Q1 25 | — | $-1.19 | ||
| Q4 24 | — | $-0.51 | ||
| Q3 24 | — | $-0.37 | ||
| Q2 24 | $-0.72 | $-0.71 | ||
| Q1 24 | — | $-0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $840.5K | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.1M | $4.0M |
| Total Assets | $13.4M | $16.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $840.5K | $8.6M | ||
| Q3 25 | — | $16.6M | ||
| Q2 25 | — | $6.9M | ||
| Q1 25 | — | $9.9M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.8M | ||
| Q2 24 | $4.5M | $8.4M | ||
| Q1 24 | — | $3.2M |
| Q4 25 | $13.1M | $4.0M | ||
| Q3 25 | $14.1M | $5.1M | ||
| Q2 25 | $15.0M | $3.0M | ||
| Q1 25 | — | $-23.6M | ||
| Q4 24 | — | $-8.9M | ||
| Q3 24 | — | $-5.2M | ||
| Q2 24 | $4.7M | $-7.6M | ||
| Q1 24 | — | $-4.8M |
| Q4 25 | $13.4M | $16.3M | ||
| Q3 25 | $14.3M | $18.7M | ||
| Q2 25 | $15.4M | $10.3M | ||
| Q1 25 | — | $12.1M | ||
| Q4 24 | — | $6.6M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | $5.1M | $11.2M | ||
| Q1 24 | — | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-733.1K | $-6.3M |
| Free Cash FlowOCF − Capex | — | $-6.3M |
| FCF MarginFCF / Revenue | — | -459.9% |
| Capex IntensityCapex / Revenue | — | 2.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-20.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-733.1K | $-6.3M | ||
| Q3 25 | $-1.1M | $-2.5M | ||
| Q2 25 | $-716.9K | $-5.8M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | $-738.5K | $-1.1M | ||
| Q1 24 | — | $-4.5M |
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $-1.2M | ||
| Q1 24 | — | $-4.6M |
| Q4 25 | — | -459.9% | ||
| Q3 25 | — | -184.3% | ||
| Q2 25 | — | -417.6% | ||
| Q1 25 | — | -583.1% | ||
| Q4 24 | — | -86.5% | ||
| Q3 24 | — | -253.7% | ||
| Q2 24 | — | -96.2% | ||
| Q1 24 | — | -271.5% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.13× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
